These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 21068143)

  • 1. Donor pre-treatment with everolimus or cyclosporine does not reduce ischaemia-reperfusion injury in a rat kidney transplant model.
    Martinez-Palli G; Hirose R; Liu T; Xu F; Dang K; Feiner J; Serkova NJ; Niemann CU
    Nephrol Dial Transplant; 2011 Jun; 26(6):1813-20. PubMed ID: 21068143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Supplemental hydrogen sulphide protects transplant kidney function and prolongs recipient survival after prolonged cold ischaemia-reperfusion injury by mitigating renal graft apoptosis and inflammation.
    Lobb I; Mok A; Lan Z; Liu W; Garcia B; Sener A
    BJU Int; 2012 Dec; 110(11 Pt C):E1187-95. PubMed ID: 23157304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sirolimus delays recovery of rat kidney transplants after ischemia-reperfusion injury.
    Fuller TF; Freise CE; Serkova N; Niemann CU; Olson JL; Feng S
    Transplantation; 2003 Dec; 76(11):1594-9. PubMed ID: 14702530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detrimental effects of prolonged warm renal ischaemia-reperfusion injury are abrogated by supplemental hydrogen sulphide: an analysis using real-time intravital microscopy and polymerase chain reaction.
    Zhu JX; Kalbfleisch M; Yang YX; Bihari R; Lobb I; Davison M; Mok A; Cepinskas G; Lawendy AR; Sener A
    BJU Int; 2012 Dec; 110(11 Pt C):E1218-27. PubMed ID: 23046222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of chronic allograft nephropathy at late stages using everolimus or FTY720 in combination with cyclosporine.
    Roos M; Liu S; Strobl M; Schmaderer C; Baumann M; Heemann U; Lutz J
    Transplant Proc; 2008 Dec; 40(10):3731-6. PubMed ID: 19100477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Donor preconditioning with a calcineurin inhibitor improves outcome in rat syngeneic kidney transplantation.
    Shihab FS; Bennett WM; Andoh TF
    Transplantation; 2009 Feb; 87(3):326-9. PubMed ID: 19202436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Everolimus and reduced cyclosporine trough levels in maintenance heart transplant recipients.
    Schweiger M; Wasler A; Prenner G; Stiegler P; Stadlbauer V; Schwarz M; Tscheliessnigg K
    Transpl Immunol; 2006 Jun; 16(1):46-51. PubMed ID: 16701176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients.
    Tedesco-Silva H; Vitko S; Pascual J; Eris J; Magee JC; Whelchel J; Civati G; Campbell S; Alves-Filho G; Bourbigot B; Garcia VD; Leone J; Esmeraldo R; Rigotti P; Cambi V; Haas T;
    Transpl Int; 2007 Jan; 20(1):27-36. PubMed ID: 17181650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal function outcomes in kidney transplant recipients after conversion to everolimus-based immunosuppression regimen with CNI reduction or elimination.
    Cataneo-Dávila A; Zúñiga-Varga J; Correa-Rotter R; Alberú J
    Transplant Proc; 2009 Dec; 41(10):4138-46. PubMed ID: 20005355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Everolimus with very low-exposure cyclosporine a in de novo kidney transplantation: a multicenter, randomized, controlled trial.
    Salvadori M; Scolari MP; Bertoni E; Citterio F; Rigotti P; Cossu M; Dal Canton A; Tisone G; Albertazzi A; Pisani F; Gubbiotti G; Piredda G; Busnach G; Sparacino V; Goepel V; Messa P; Berloco P; Montanaro D; Veroux P; Federico S; Bartezaghi M; Corbetta G; Ponticelli C
    Transplantation; 2009 Nov; 88(10):1194-202. PubMed ID: 19935373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of everolimus on cytokines, oxidative stress, and renal histology in ischemia-reperfusion injury of the kidney.
    Suyani E; Derici UB; Sahin T; Ofluoglu E; Pasaoglu H; Erdem O; Barit G; Reis KA; Erten Y; Arinsoy T; Sindel S
    Ren Fail; 2009; 31(8):698-703. PubMed ID: 19814637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of delayed graft function and wound healing complications after deceased-donor kidney transplantation is not affected by de novo everolimus.
    Albano L; Berthoux F; Moal MC; Rostaing L; Legendre C; Genin R; Toupance O; Moulin B; Merville P; Rerolle JP; Bayle F; Westeel PF; Glotz D; Kossari N; Lefrançois N; Charpentier B; Blanc AS; Di Giambattista F; Dantal J;
    Transplantation; 2009 Jul; 88(1):69-76. PubMed ID: 19584683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term results of kidney transplantation with cyclosporine- and everolimus-based immunosuppression.
    Iaria G; Pisani F; Iorio B; Lucchesi C; De Luca L; Ielpo B; D'Andria D; Tariciotti L; Tisone G
    Transplant Proc; 2006 May; 38(4):1018-9. PubMed ID: 16757249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can cyclosporine blood level be reduced to half after heart transplantation?
    Wang SS; Chou NK; Chi NH; Huang SC; Wu IH; Wang CH; Yu HY; Chen YS; Tsao CI; Ko WJ; Shun CT
    Transplant Proc; 2010 Apr; 42(3):930-3. PubMed ID: 20430207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FTY720 reduces extracellular matrix expansion associated with ischemia-reperfusion induced injury.
    Delbridge MS; Shrestha BM; Raftery AT; El Nahas AM; Haylor J
    Transplant Proc; 2007 Dec; 39(10):2992-6. PubMed ID: 18089307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glutamine donor pretreatment in rat kidney transplants with severe preservation reperfusion injury.
    Fuller TF; Rose F; Singleton KD; Linde Y; Hoff U; Freise CE; Dragun D; Niemann CU
    J Surg Res; 2007 Jun; 140(1):77-83. PubMed ID: 17292409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Everolimus with reduced-dose cyclosporine in de novo renal transplant recipients: Philippine experience.
    Li JT; Danguilan RA; Cabanayan-Casasola CB; Talusan-Tomacruz Y; Ona ET
    Transplant Proc; 2008 Sep; 40(7):2211-3. PubMed ID: 18790195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Immunosuppression in kidney donors with rapamycin and tacrolimus. Proinflammatory cytokine expression].
    Cicora F; Roberti J; Lausada N; González P; Guerrieri D; Stringa P; Raimondi C
    Medicina (B Aires); 2012; 72(1):3-9. PubMed ID: 22257448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conversion of stable kidney transplant recipients from a twice-daily to once-daily everolimus regimen.
    Carmellini M; Collini A; Ruggieri G; Bernini M
    Transplant Proc; 2010 May; 42(4):1312-3. PubMed ID: 20534288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sirolimus-based therapy with or without cyclosporine: long-term follow-up in renal transplant patients.
    Morales JM; Campistol JM; Kreis H; Mourad G; Eris J; Schena FP; Grinyo JM; Nanni G; Andres A; Castaing N; Brault Y; Burke JT
    Transplant Proc; 2005 Mar; 37(2):693-6. PubMed ID: 15848504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.